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As part of an effort to identify druggable diacylglycerol kinase alpha (DGKa) inhibitors, we used an in-
silico approach based on chemical homology with the two commercially available DGKa inhibitors
R59022 and R59949. Ritanserin and compound AMB639752 emerged from the screening of 127 com-
pounds, showing an inhibitory activity superior to the two commercial inhibitors, being furthermore
specific for the alpha isoform of diacylglycerol kinase. Interestingly, AMB639752 was also devoid of
serotoninergic activity. The ability of both ritanserin and AMB639752, by inhibiting DGKa in intact cells,
to restore restimulation induced cell death (RICD) in SAP deficient lymphocytes was also tested. Both
compounds restored RICD at concentrations lower than the two previously available inhibitors, indi-
cating their potential use for the treatment of X-linked lymphoproliferative disease 1 (XLP-1), a rare
genetic disorder in which DGKa activity is deregulated.
© 2018 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The atypical lipid kinases DGK (diacylglycerol kinases) catalyze
the phosphorylation of diacylglycerol (DAG) to phosphatidic acid
(PA) (Fig. 1) [1].
Both these molecules act as second messengers regulating a
plethora of biological processes such as cell proliferation and
motility, immune responses, glucose metabolism, and cardiovas-
cular responses [2].sity Vita e Salute San Raffaele,
nal Medicine and Center for
monte Orientale, via Solaroli
raziani), gianluca.baldanzi@
Masson SAS. This is an open accessDGKs permit to control the cellular concentration of these two
bioactive lipids, terminating the DAG signaling and increasing the
concentration of PA [3], and it is not surprising that an up- or down-
regulation of DGKs has been linked with several pathological
conditions such as cancer, epilepsy, Parkinson's disease, bipolar
disorders, cardiac hypertrophy, type II diabetes, and hypertension
[4]. Among the ten human isoforms of DGK (a, b, g, d, ε, z, h, q i, and
k) [5], the most studied one is the a isoform which is particularly
expressed in the central nervous system, spleen, thymus, T cells,
and lungs. Interestingly, it has been shown that the inhibition of the
a form can be a valuable strategy for the discovery of novel anti-
cancer compounds [6]. Indeed, this enzyme is overexpressed in
several malignancies, particularly in hepatocellular carcinoma and
melanoma cells, showing pro-tumoral and anti-immunogenic
properties, and its inhibition damages cancer cells viability,
blocks the angiogenetic process and, remarkably, it increases the T
cells activation [7,8].
Another disease linked with overactivation of DGKa is the X-article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. DAG is phosphorylated by diacylglycerol kinases to phosphatidic acid.
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munodeficiency of genetic origin characterized by dysgammaglo-
bulinaemia and poor CD8þ cytotoxic T cell function, with some
patients developing lymphomas of the bowel, peritoneum, and
brain [9]. Most importantly, XLP-1 patients face significant
morbidity and mortality in response to Epstein-Barr virus (EBV)
infection, which causes marked lymphoproliferative disease,
featuring fulminant infectious mononucleosis (FIM), cytopenia,
liver failure, hepatosplenomegaly, and/or hemophagocytic lym-
phohistiocytosis [10]. XLP-1 is due to loss of function mutations of
the 128-amino acid signaling lymphocytic activation molecule
(SLAM)eassociated protein (SAP) adaptor molecule. Loss of SAP in
XLP-1 patients impairs both adaptive and innate immunity,
resulting in several immunologic alterations. Notably, a block in
NKT-cell development [11]; decreased NK and CD8þ cytotoxicity,
specifically toward EBV-infected B-cell targets [12]; impaired CD4þ
T helper function and B cell conjugation, resulting in reduced
germinal center formation and ineffective antibody production [13]
and resistance to restimulation induced cell death (RICD), a ho-
meostatic mechanism preventing excessive T cell proliferation [14].
Interestingly, the signaling alterations reported in SAP deficient
cells are consistent with a reduced DAG signaling due to increased
DGKa activity [15]. Indeed, TCR signaling inhibits DGKa through a
signaling pathway that requires PLC activity and calcium but also
the expression of SAP [15]. Thus, T cells from XLP-1 patients, which
lack functional SAP, feature deregulated DGKa activity, which is a
main contributor of the defective lymphocyte responses observed
both in XLP-1 patients and in SAP KO mice. Indeed, pharmacolog-
ical inhibition of DGKa restores RICD in lymphocytes from XLP-1
patients and prevents the excessive CD8þ T cell expansion and
interferon-g production that occur in SAP-deficient mice after
lymphocytic Choriomeningitis virus infection [16]. Collectively,
these data highlight DGKa as a viable therapeutic target to reverse
the life-threatening EBV-associated immunopathology that occurs
in XLP-1 patients.
To date, a handful of DGKs inhibitors have been discovered, but
some drawbacks are associated with their use as drugs such as low
potency, lack of selectivity, off-target effects and poor pharmaco-
kinetic properties. In Fig. 2 are reported the best documented DGK
inhibitors, which can be gathered in three main groups: i) allosteric
inhibitors; ii) DAG analogues and iii) competitive inhibitors at the
ATP binding site.
In the class of allosteric inhibitors, the two compounds R59949
and R59022 are the most important discovered to date [17,18],
show selectivity for DGKa [19] and they have been important
pharmacological tools for studying the role of DGKs in cells. The
IC50 values of R59022 and R59949 are dependent by assay condi-
tions: using whole cell lysates of DGKa overexpressing Cos-7 cells
in a nonradioactive assay method, the IC50 values of R59022 and
R59949 were approximately 25 mM and 18 mM, respectively [19,20].
In the original reports, however, R59022 featured an IC50 of 3.8 mM
on erythrocyte ghosts while R59949 displayed an IC50 of 0.3 mM on
platelet membranes [17,18]. It has been postulated that R59949binds to the catalytic domain of DGKa in synergy with Mg-ATP
without affecting DAG binding. Putatively R59949 acts by binding
in proximity to the Mg-ATP site or promoting a conformational
change of the enzyme that exposes both Mg-ATP and R59949
binding sites [20]. However, their use in vivo is severely limited by
poor pharmacokinetic properties, and several off-target activities
(https://www.ebi.ac.uk/chembl/). Despite these drawbacks and its
short half-life, R59022 has been used in mice with positive results
in glioblastoma models and in XLP-1 [16,21]. Based on structural
similarity with R59022, ritanserin was recently characterized as an
active non-competitive inhibitor of DGKa with an IC50 around
20 mM [22]. Structural studies support a contiguous ligand-binding
site composed of C1, DAGKc, and DAGKa domains in the DGKa
active site for this class of inhibitors [23,24]. Both ritanserin, and
R59022/R59949 are also antagonists of serotonin receptors. For
example, ritanserin was indeed originally described as a selective
5-HT2A (Ki¼ 0.45 nM) and 5-HT2C receptor (Ki¼ 0.71 nM) antag-
onist and underwent clinical trials for the treatment of schizo-
phrenia and other mental diseases [25].
The class of DAG analogues has not produced potent and phar-
macologically useful DGK inhibitors to date with dioctanoyl-
ethylene glycol (Ki¼ 58 mM) and 1-monooleolylglycerol
(Ki¼ 91 mM) the two most potent inhibitors found [26,27]. To note
that phorbol esters, well-known DAG mimetic on PKC, are active
only with the b and g isoform, while they have no activity on the
other eight isoforms [28,29]. Finally, it is important to highlight the
problem of identifying ATP competitive inhibitors of DGKs. The
reason lays in their different ATP binding pocket compared to
serine-tyrosine kinases but also to lipid kinases such as PI3Ks. The
different architecture of the ATP binding pocket is exemplified by
the total lack of activity of the pan-kinase inhibitor staurosporine
on DGKs [28]. Very recently, a compound named CU-3 was iden-
tified via high throughput screening. In a non-radioactive assay
method, CU-3 was able to inhibit DGKawith an IC50 value of 0.6 mM
in DGKa overexpressing Cos-7 cells. Moreover, CU-3 acts as a
competitive inhibitor of DGKa that reduces affinity of DGKa for ATP,
but not diacylglycerol or phosphatidylserine [30].
The goal of this work was therefore to identify novel druggable
inhibitors of DGKa, for the treatment of XLP-1 using a virtual
screening approach. As there is no detailed structural information
on DGKa catalytic domain, we searched for new inhibitors using
R59022 and R59949 as templates to explore the chemical space via
2D/3D virtual screening approaches. Herein, we report that out of
127 compounds tested, ritanserin and AMB639752 were more
active than the lead inhibitors R59022 and R59949. We also show
that both compounds can restore TCR pro-apoptotic signaling and
RICD in SAP-deficient T cells, suggesting their use for treatment of
EBV-induced FIM in XLP-1 patients. Moreover, AMB639752 does
not perturb serotonin signaling indicating an increased selectivity.
2. Result and discussion
2.1. In silico drug discovery
Starting from the structure of R59949 and R59022, we
commenced with a fast in-silico molecular comparison method to
calculate molecular similarity of target substances to both refer-
ence compounds (2D-similarity-based virtual screening). In brief,
the 2D fingerprint-based methods encode the structural features of
molecules as bit strings, whereby each bit indicates the presence or
absence of pre-defined structural patterns such as atom sequences,
electronic configurations, atom pairs, and ring systems. We used
the PubChem library and selected molecules with a Tanimoto co-
efficient 0.75 in comparison with R59949 (reference compound).
Five compounds emerged from this screening (R59022, altanserin,
Fig. 2. DGKs inhibitors: state of the art.
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compounds were already evaluated as serotonin receptor antago-
nists, we decided to select other 24 serotonin receptor antagonists
as negative control for DGKa inhibition (Supplementary Table S1).
Of those, only 21 compounds resulted commercially available
(R59022, ritanserin, ketanserin, pimozide and 17 negative controls)
and were included in the subsequent screen. Subsequently, we
used an in-silico 3D approach using R59022 and R59949 as query
ligands to identify in the ZINC database24 compounds with similar
three-dimensional shape and electrostatic properties compared
with the two standards.Of note, our query compounds contain several rotatable single
bonds and their bioactive conformations are unknown. Therefore,
in our shape-based virtual screening strategy we explored a range
of possible conformations of templates by screening against the
most stable conformations of both R59022 (9 conformers) and
R59949 (6 conformers) generated with Omega [31]. After genera-
tion of conformers for each ZINC compound in the “drug-now”
subset, the 3D shape comparison between R59s and the molecules
in the ZINC library was performed by ROCS [32], in which shape is
approximated by atom-centered overlapping Gaussians and cal-
culates the maximal intersection of the volume of two molecules.
Fig. 3. Virtual screening protocols details. A) Flow chart outlining the protocol used in the 2D-Similarity-based virtual screening. B) Flow chart outlining the protocol used in the 3D-
Similarity-based virtual screening.
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electrostatics with the program EON [33]. Electrostatic rank was
based on an electrostatic Tanimoto score, ranging from 0 to 2,
where 2 represents an exact match of both shape and functional
groups between two molecules. We selected the top 150 com-
pounds and purchased the 106 compounds that were commercially
available (Fig. 3B). Full details for these compounds including their
structures, Tanimoto ranks and chemical identification numbers
are provided in Supplementary Table S2.2.2. Biological results
To identify the active compounds between those emerged from
the two in-silico screenings, all the candidates were dissolved in
DMSO and tested at a concentration of 100 mM for the ability to
inhibit DGKa using equal amounts of DMSO as control. Assay uses
OST-DGKa overexpressing cell lysates in presence of saturating
exogenous DAG and ATP [34]. Due to the poor solubility, risperi-
done and AMB9107756 were not included in this assay, resulting in
127 compounds tested. Each inhibitor was tested in duplicate, and
DGKa activity was expressed as percentage of residual DGKa ac-
tivity compared to DMSO control in the same assay. Out of the 127
compounds, we identified 17 compounds capable of reducing OST-
DGKa activity at least by 25% (Table 1). As expected, our reference
inhibitors R59022 and R59949 featured 73% and 72% inhibition
respectively, confirming the quality of data obtained. Interestingly,
ritanserin and above all the new entry AMB639752 inhibited OST-
DGKa better than R59022 and R59949, thus representing novel
DGKa inhibitors. In order to confirm the structure and purity of
AMB639752, NMR structural characterization, mass analysis and
elemental analysis were carried out, verifying the correctness of the
structure (see “Experimental protocols” section).
Surprisingly, in this assay, more than 60% of the compoundsstimulated DGKa activity, with some compounds enhancing the
enzyme activity by several folds. We can confirm that the most
active one, fluoxetine, significantly enhances DGKa activity in vitro
(Fig. S1). As reported for the parental compounds, these molecules
may enhance affinity for Mg-ATP or promote an active enzyme
conformation by inserting in an allosteric pocket [23,24]. However,
for the moment, we did not investigate these compounds further.2.3. Potency and isoform specificity of ritanserin and AMB639752
Tomeasure the inhibitor potency, we determined the IC50 values
for active compounds by measuring the residual OST-DGKa activity
over a dose range of inhibitor concentrations (0.1, 0.3, 1.0, 3.0, 10.0,
30.0 and 100.0 mM). For R59022 and R59949 we measured IC50
values of 19.7± 3.0 mM and 10.6± 3.2 mM respectively, comparable
to previous reports using similar assay conditions [19,20].
Conversely, we found IC50 values of 16.7± 4.6 mM for ritanserin and
4.3± 0.6 mM for AMB639752 (Fig. 3). Those results indicate a su-
perior potency of AMB639752 with respect to both ritanserin and
the template compounds.
127 molecules were dissolved in DMSO and tested at 100 mM for
the capacity to inhibit DGKa in homogenates of OST-DGKa over-
expressing MDCK cells. Dose response of the most active com-
pounds along with their IC50 values is shown. Data from at least
three independent experiments performed in triplicate.
Concerning similarity to R59s, AMB639752 is different with
respect to their chemical scaffold, but similar in three-dimensional
shape, as demonstrated by their shape Tanimoto's ranks (0.623,
Supplementary Information Table S2). AMB639752 is also electro-
statically similar to R59949, with an electrostatic Tanimoto of 0.745
(Fig. 4).
To check the isoform specificity of AMB639752, we tested it
along with R59s, for the ability to inhibit DGKa, DGKz (the other
Table 1
Compounds that inhibit DGKa at least by 25%.
Sl.No Code Name Residual DGKa activity at 100 mM (% of control)
1. Amb639752 4
2. R103 ritanserin 17
3. R59022 diacylglycerol kinase inhibitor I 27
4. R59949 diacylglycerol kinase inhibitor II 28
5. Amb3494010 39
6. Amb19541048 49
7. Amb8223059 50
8. Amb11070312 57
9. H0972 haloperidon 62
10. Amb242047 64
11. Amb20056316 67
12. Amb8244320 68
13. Amb110991 68
14. E0925 ebastine 69
15. Amb252835 72
16. U0085 urapidil 75
17. Amb19382197 75
Fig. 4. Biochemical screen for novel DGKa inhibitors.
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distantly related DGKq. Also at the highest concentration of 100 mM,
R59022, R59949 and AMB639752 are highly specific against DGKa
as they completely inhibit DGKa (68%, 81%, 93% respectively,
Fig. 5A) while they do not have significant effects on DGKz (Fig. 5B)
and DGKq (Fig. 5C). Similar results were reported for ritanserin [22]
indicating that this class of inhibitors is highly specific for DGKa.2.4. Activity of compounds on serotonin receptors
As R59022, R59949 and ritanserin feature a dual activity as
DGKa inhibitors and serotonin receptor antagonists [22], we
investigated whether also AMB639752 affects serotonin signaling.
To this purpose, we measured the effect of serotonin on PMA-
induced oxidative burst in human monocytes. As previously
Fig. 5. 2D, 3D and shape of R59949 and Amb639752 chemical structures. Electrostatic surfaces are color coded (red for negative and blue for positive).
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values [35]. When tested at 10 mM, the known serotonin receptor
antagonists ritanserin and ketanserin impaired serotonin action,
while pure DGKa inhibitors such as CU-3 had no effect (Fig. 7).
These data indicate that this assay is sensitive to perturbations
in serotonin signaling independently of activity against DGKa.
AMB639752, despite sharing surface similarity with R59949 and
ritanserin, did not affect serotonin action demonstrating that it is
not a serotonin receptor antagonist. This interesting observation
suggests a better pharmacological profile for AMB639752, which
inhibits DGKa without off-target effects on serotonin receptors.
2.5. DGKa specific inhibitors restores RICD in SAP deficient T cells
The defective RICD observed in T cells from XLP-1 patients was
rescued by silencing DGKa expression or by pre-treatment with
DGKa inhibitors R59949 or R59022 at 5e10 mM [16]. Interestingly,
R59022 also showed beneficial effects in an in vivomodel of XLP-1,
but its poor pharmacological proprieties make its use in human
patients unlikely. We therefore tested the effect of ritanserin and
AMB639752 on RICD sensitivity of SAP-deficient T cells. As addi-
tional controls, we also included ketanserin to evaluate the
contribution of serotonin antagonism to the effects observed and
CU-3 as representative of a different class of molecules inhibiting
DGKa by competing with ATP. To model XLP-1 T cells in vitro, we
previously silenced SAP in Jurkat cells [15], a widely used cellularFig. 6. AMB639752 is DGKa specific. A, B, C) 293T cells were transfected with different DG
enized. AMB639752, R59022 and R59949 were tested at 100 mM for their capacity to inhibit
independent experiments performed in triplicate.model for RICD mediated by FAS induction [36]. RICD was induced
by treatment with immobilized anti-CD3 antibody (OKT3, 50 mg/
ml) or PHA (50 mg/ml) [37]. As expected, SAP-silenced Jurkat cells
showed reduced RICD compared to cells transfected with a control
siRNA, making this an easy model for testing our inhibitors (Fig. 8B
and C). The inhibitors were not overly toxic to Jurkat cells as 24-h
treatment at 1 mM doses did not decrease the viability of Jurkat
cells, apart for a modest toxicity of CU-3 (Fig. 8A). At this concen-
tration, ritanserin, AMB639752 and CU-3 significantly promoted
RICD in SAP-silenced Jurkat cells, restoring death to levels noted in
Jurkat control cells after either anti-CD3 (Fig. 8B) or PHA (Fig. 8C)
treatment. Conversely, ketanserin only had a modest effect (Fig. 8B
and C). These data indicate that the new DGKa inhibitors identified
by our screen can restore RICD in this cell model of XLP-1.
Furthermore, our results suggest these effects result from inhibit-
ing DGKa independently of eventual activity on serotonin
receptors.
To assess inhibitor efficacy in a more physiological context, we
also modelled XLP-1 by silencing SAP in primary peripheral blood T
lymphocytes (PBL) and re-stimulating them with increasing doses
of anti-CD3 antibody (OKT3 1e100 ng/ml, 24 h). In these assay
conditions, 30-min pre-treatment with R59949 or R59022 restored
RICD sensitivity in SAP silenced cells at concentrations of 5e10 mM
[16]. Also in this setting, ritanserin does not influence RICD induced
by CD3 triggering in control siRNA-transfected cells, indicating that
it is neither affecting TCR signaling nor is cytotoxic to primary cellsK isoforms (A- DGKa, Be DGKz, Ce DGKq respectively) or empty vectors and homog-
the DGK activity of the different homogenates. Data are means ± S.E.M. of at least three
Fig. 7. AMB639752 does not affect serotonin signaling. Human monocytes were pre-incubated for 1 h with the indicated drugs (10 mM) in absence or presence of serotonin (1 mM)
and then stimulated with PMA 1 mM for 30min (, control unstimulated cells, - PMA treated cells, PMA and serotonin stimulated cells). Results are expressed as nmoles of
reduced cytochrome C/106 cells. Data are means± S.E.M. of 6 independent experiments performed in triplicate.
Fig. 8. DGKa inhibitors rescues RICD in SAP deficient Jurkat cells. Jurkat T cells (control shRNA- and SAP shRNA ) were treated with ritanserin, AMB639752, CU-3 or ketanserin
(1 mM) and plated on a 96 well flat bottom plate previously coated with nothing (A), anti CD3 (OKT3 50 mg/ml, B) and PHA (50 mg/ml, C). After 24 h of incubation, live cells were
counted using the trypan blue exclusion assay and expressed as % of cell loss respect to untreated controls. The data are the means of ±SEM of at least five experiments performed in
triplicate. D) Western blot confirming the silencing of SAP in SAP shRNA Jurkat cells compared with control shRNA Jurkat cells.
S. Velnati et al. / European Journal of Medicinal Chemistry 164 (2019) 378e390384at concentrations between 1 and 10 mM. Conversely, ritanserin
completely rescued the apoptotic defect in SAP-deficient T cells at
concentrations as low as 1 mM (Fig. 9A). We used ritanserin 10 mM
as reference for further sets of experiments (we always compare
controls and SAP silenced lymphocytes from the same donors as
there is a large individual variability in RICD sensitivity).
AMB639752 demonstrated similar activity, not affecting RICD
sensitivity in control lymphocytes, but fully rescuing the RICDdefect of SAP-deficient cells also at 1 mM concentration and with a
potency equal to 10 mM ritanserin (Fig. 9B). Whenwe tested the ATP
competitive DGKa inhibitor CU-3, we observed a modest induction
of RICD in control-silenced lymphocytes that is absent in the other
molecules tested. In SAP-silenced cells, CU-3 improved RICD
sensitivity approaching ritanserin levels when used at concentra-
tions 5 mM, (Fig. 9C). These observations suggest that CU-3 has a
narrower therapeutic window with some likely cytotoxicity at
Fig. 9. DGKa inhibitors rescues RICD in SAP deficient T cells. Lymphocytes from normal subjects were transfected with control or SAP specific siRNA. A, B, C, D) After 4 days, the cells
were restimulated with increasing doses of CD3 agonist OKT3 (1, 10, 100 ng/ml) in presence or absence of (A) ritanserin, (B) AMB639752, (C) CU-3, (D) ketanserin (1, 5, 10 mM). 24 h
later, the % of cell loss was evaluated by PI staining. Data are the mean± SEM of at least three independent experiments performed in triplicate.
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verify if serotonin receptor antagonism could contribute to the
observed effects. Interestingly, ketanserin had no effect on RICD in
control cells, but partially increased RICD in SAP-silenced T cells,
although this effect was not statistically significant (Fig. 9D). These
findings are in linewith our Jurkat cell experiments, suggesting that
inhibition of DGKa is an efficient strategy to rescue of RICD in XLP-1
models, while serotonin antagonism plays a minor role.
In summary, these data confirm that ritanserin and AMB639752
rescue RICD susceptibility in T cell models of XLP-1. Our observa-
tions are consistent with those on DGKa-silenced cells [16], indi-
cating that DGKa is a relevant pharmacologic target for restoring
RICD and immune homeostasis in XLP-1 patients.2.6. DGKa specific inhibitors potentiates TCR signaling and induces
expression of the pro-apoptotic nuclear receptors Nur77 and Nor1
in SAP deficient T cells
Silencing DGKa expression or pre-treatment with DGKa in-
hibitors R59949 or R59022 boosts RICD in SAP-deficient T cells by
selectively restoring TCR-induced upregulation of the pro-apoptotic
orphan nuclear receptors NUR77 (NR4A3) and NOR1 (NR4A1) [16].
To verify if ritanserin and AMB639752 acts through the same
mechanism, we measured TCR-dependent induction of NR4A1 and
NR4A3 in SAP-silenced activated T cells. Indeed, ritanserin potenti-
ated TCR-induced NR4A1 expression in control cells and to a lesser
extent, in SAP silenced cells. In contrast, AMB639752 was more
active in rescuing NR4A1 and NR4A3 in SAP-silenced activated Tcells
(Fig. 9). These observations suggest that both ritanserin and espe-
cially AMB639752 restore RICD by promoting the expression and
apoptotic activity of NR4A1 and NR4A3 (see Fig. 10).3. Conclusion
Summarizing, the purpose of this project was to discover novel
inhibitors against DGKa suitable for future clinical trials in XLP-1
patients. To find potentially drug candidates, we explored in-
silico the chemical space of ZINC by using the two commercially
available inhibitors (R59022 and R59949) as templates. We
assembled a library of 127 compounds using this approach,
including both uncharacterized molecules and a series of com-
pounds already in clinical use or development.
By screening this library, we found 17 active inhibitors, with two
more active than the lead compounds: the compound AMB639752Fig. 10. DGKa inhibitors rescues Nur77 and Nor1 expression in SAP deficient T cells. Lympho
days, the cells were restimulated with the CD3 agonist OKT3 (10 mg/ml) in presence or ab
NR4A1 and NR4A3 evaluated by quantitative PCR using GUSB as a reference. Data are theand ritanserin. We defined the IC50 values of ritanserin
(16.7± 4.5 mM) and AMB639752 (4.3± 0.6 mM) for inhibiting DGKa.
Thus, IC50 value of AMB639752 compares favourably with ritan-
serin, R59022 (19.7± 3.0 mM) and R59949 (10.6± 3.2 mM) in the
same assay. Interestingly 60% of the compounds in the library acted
as activators and not inhibitors of DGKa (see supporting informa-
tion). These compounds might bind to the same pocket as R59949
and increase affinity for Mg-ATP or stabilize an active conforma-
tion. Further studies will explore whether these DGKa activators
may offer interesting opportunities for the control of DAG meta-
bolism in pathological settings such as inflammation.
AMB639752 maybe a promising molecule for a drug optimiza-
tion program, as it potently inhibits DGKa without influencing se-
rotonin signaling on the contrary of ritanserin. AMB639752 was
highly active in cell-based assays, with negligible cytotoxicity at
concentrations used for the two commercially available DGK in-
hibitors. Moreover, it did not alter RICD sensitivity of control (SAP-
sufficient) lymphocytes. Both ritanserin and AMB639752 restore
RICD in SAP-deficient cells at 1, 5 and 10 mM concentration,
consistent with DGKa inhibition. At these doses, neither compound
displayed toxicity nor impaired TCR signaling. Both drugs restored
the induction of key pro-apoptotic molecules NUR77 and NOR1 in
SAP-deficient cells, but AMB639752 was far more active. This in-
dicates that similarly to R59s and DGKa silencing, ritanserin and
AMB639752 are not simple TCR signal enhancers, but selectively
influence SAP-dependent downstream signaling outcomes that
promote RICD. Altogether, these observations support our initial
hypothesis that excessive DGKa activity contributes to XLP-1
pathogenesis and suggest that we are moving in the right direc-
tion to find new compounds for countering life threatening disease
complications in this disease (e.g. EBV-induced FIM).4. Experimental protocols
4.1. Structural confirmation for AMB639752
AMB639752 or 1-(2,5-dimetil-1H-indol-3-yl)-2-(4-(furan-2-
carbonil)piperazin-1-yl)etan-1-one: yellowish solid; 1H NMR
(300MHz, CDCl3): d¼ 8.70 (br s, 1H), 7.74 (d, J¼ 8.2 Hz, 1H), 7.47 (s,
1H), 7.26 (s, 1H), 7.13 (s, 1H), 7.07 (d, J¼ 8.2 Hz), 6.98 (br d, 1H), 6.47
(br d, 1H), 3.92 (br s, 4H), 3.85 (s, 2H), 2,79 (br s, 4H), 2,74 (s, 3H),
2.44 (s, 3H); MS (ESI):m/z¼ 366 [MþH]þ; elemental analysis calcd
(%) for C21H23N3O2: C 69.02, H 6.34, N 11.50: found: C 69.23, H 6.58,
N 11,33.cytes from normal subjects were transfected with control or SAP specific siRNA. After 4
sence of ritanserin or AMB639752 at 10 mM concentration. 4 h later, the expression of
mean ± SEM of at least four independent experiments.
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Madin-Darby canine kidney cells (MDCK) stably expressing One
Strep Tag DGKa (OST-DGKa) were prepared by infectingMDCK cells
with a vector expressing an inducible OST tagged DGKa constructs
[38]. MDCK cells infected with empty vector were used as controls.
MDCK cells were cultured in MEM (Minimal Essential Medium)
with 5% FBS (Fetal Bovine Serum) and 1% antibiotic-antimycotic
solution. Routinely, cells were split every 3e4 days with Trypsin-
EDTA 0.25% in standard 100mm dishes.
Human embryonic kidney 293T cells (10 cm2 plates) were
cultured in RPMI with 10% FBS and 1% penicillin/streptomycin.
Generation of Jurkat shRNA SAP and the Jurkat shRNA control
was described in Ref. [15]. Jurkat cells were cultured in RPMI-
GlutaMAX (Life Technologies) with 10% FBS (Lonza) and 1% peni-
cillin/streptomycin (Life Technologies).
4.3. Primary cells
Peripheral blood mononuclear cells (PBMCs) were isolated from
healthy anonymous human buffy coats (provided by the Trans-
fusion Service of Ospedale Maggiore della Carita, Novara, Italy) by
Ficoll-Paque PLUS (GE Healthcare) density gradient centrifugation,
washed, and resuspended at 2 106 cell/ml in RPMI-GlutaMAX
containing 10% heat inactivated FCS, 2mM glutamine, and 100 U/
ml of penicillin and streptomycin. T cells were activated with 1 mg/
ml anti-CD3 (clone OKT3) and anti-CD28 (clone CD28.2) antibodies.
After 3 days, activated T cells were washed and cultured in medium
supplemented with 100 IU/ml rhIL-2 (Peprotech) at 1.2 106 cells/
mL for 7 days by changing media for every 2e3 days.
Human monocytes were isolated from healthy anonymous hu-
man buffy coats (provided by the Transfusion Service of Ospedale
Maggiore della Carita, Novara, Italy) by the standard technique of
dextran sedimentation and Histopaque (density¼ 1.077 g cm3,
Sigma-Aldrich, Milano, Italy) gradient centrifugation (400g,
30min, room temperature) and recovered by fine suction at the
interface, as described previously [35]. Purified monocytes pop-
ulations were obtained by adhesion (90min, 37 C, 5% CO2) in
serum-free RPMI 1640 medium (Sigma-Aldrich, Milano, Italy)
supplemented with 2mM glutamine and antibiotics. Cell viability
(trypan blue dye exclusion) was usually >98%.
4.4. Molecular modelling
All molecular modelling studies were performed on a Tesla
workstation equipped with two Intel Xeon X5650 2.67 GHz pro-
cessors and Ubuntu 11.10 (www.ubuntu.com). The protein struc-
tures and 3D chemical structures were generated in PyMOL [The
PyMOL Molecular Graphics System, version 1.3; Schr€odinger LLC:
2010].
2D-Similarity-based virtual screening. The collection of com-
pounds was retrieved from PubChem (February 2nd, 2013), this
searchable database includes chemical structures available from
published literature [39]. The structures were downloaded and
filtered using software FILTER [FILTER, version 2.0.2; OpenEye Sci-
entific Software: Santa Fe, NM. http://www.eyesopen.com]: mo-
lecular weight <500 Da and >150, logP 5, number of rotatable
bonds7, polar surface area<150, number of hydrogen bond donor
5 and number of hydrogen bond acceptor 10. Using these
criteria 252,067 structures were retrieved. First, the ChemFP Sub-
structure fingerprints were generated for the compounds using
chemfp v1.1 [chemfp, version 1.1; Dalke Scientific: Sweden, 2013.
http://chemfp.com], with the OEChem [OEChem TK, Python version
1.7.7; OpenEye Scientific Software: Santa Fe, NM. http://www.
eyesopen.com], was used to select compounds that are similar toR59949 by at least a Tanimoto cutoff of 0.75; 5 compounds were
selected (Table 1). In order to qualitatively validate the approach 24
other compounds with similar biological activity, not selected by
our method, were used as negative control (Supplementary
Table S1).
3D-Similarity-based virtual screening. The collection of com-
pounds was retrieved from ZINC (February 19th, 2014), this
searchable database includes chemical structures available from
vendors [40,41]. The “drug-now” subset, that contains molecules
with drug-like properties (molecular weight <500 Da and >150,
logP 5, number of rotatable bonds 7, polar surface area <150,
number of hydrogen bond donor5 and number of hydrogen bond
acceptor 10), was downloaded. Using these criteria, 6,366,032
structures were retrieved. An in-house Perl script was used in order
to standardize charges, enumerate ionization states, generate tau-
tomers at physiological pH range and remove PAINS substructures
62 using the FILTER and QUACPAC software from OpenEye (FILTER,
version 2.5.1.4; OpenEye Scientific Software: Santa Fe, NM, http://
www.eyesopen.com; QUACPAC, version 1.6.3.1; OpenEye Scientific
Software: Santa Fe, NM, http://www.eyesopen.com). 3,131,697
structures were retained. The latter operationwas followed by a 3D
structure optimization and conformers generation using OMEGA2
software (OMEGA, version 2.4.6; OpenEye Scientific Software:
Santa Fe, NM. http://www.eyesopen.com) [31,42]. A three dimen-
sional structures of R59022 and R59949 were built: we used
OMEGA2 software to generate 9 conformers of R59022 and 6
conformers of R59949. A RMSD cutoff of 0.75 Å was used in this
step. Successful candidates were filtered using shape matching.
ROCS software was used for 3D shape comparisons (ROCS, version
2.4.1; OpenEye Scientific Software: Santa Fe, NM. http://www.
eyesopen.com) [32]. The top 1000 structure were considered for
electrostatic comparisons, EON was used (EON, version 2.0.1;
OpenEye Scientific Software: Santa Fe, NM. http://www.eyesopen.
com) [33]. The best compounds were selected based on Tanimo-
toCombo values (ShapeTanimoto þ ElectrostaticTanimoto). At the
end the best 150 compounds were considered, 106 compounds
were commercially available and were retrieved from Ambinter
vendor (Supplementary Table S2).
All these compounds, including the two known inhibitors were
dissolved in DMSO at a concentration of 10mM AMB9107756 re-
mains undissolved and due to solubility problems ebastine (E0925)
was dissolved at 5mM, risperidone (R3030) at 1mM concentra-
tions respectively.
ATPg32P is from PerkinElmer, cell culture reagents are from
Thermo Fisher, all other chemicals were from Sigma Aldrich. CU-3
is a king gift of F. Sakane (Chiba University, Japan).4.5. Preparation of DGKa enriched homogenates
Large cultures for enzyme preparation were done by plating
5 106 cells in 245mm2 dishes. Once they reached nearly 70%
confluence, cells were treated with doxycycline (1 mg/ml, 2 days).
After 2 days of treatment, each plate was washed in cold PBS and
cells homogenized in 5ml of homogenate buffer (25mMHepes (pH
8), 20% glycerol, 135mM NaCl, 5mM ethylenediaminetetraacetic-
acid (EDTA), 1mM ethylene glycol-bis(beta-aminoethyl ether)-
N,N,N0,N'-tetraacetic acid (EGTA), 1mM sodium orthovanadate and
protease inhibitor cocktail) for each dish. Cells were collected with
a rubber scraper, homogenized by passing them through a 29G-
needle syringe 20 times and stored in aliquots at 80 C. Presence
of OST-DGKawas confirmed bywestern blotting and enzyme assay,
transduced DGKa has an activity >100 folds the endogenous DGK.
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293T cells were transiently transfected with indicated DGK
isoform plasmid DNA using Lipofectamine 3000, Invitrogen
(Carlsbad, CA). 48 h after transfection, cells were harvested and
homogenized with a 29G-needle using 500 ml/plate of homogenate
buffer for each dish and immediately stored in aliquots at 80 C.
Cells transfected with empty vector were used as controls, over-
expressed DGK has an activity >50 folds the endogenous.
4.7. DGK assay
DGK activity was assayed by measuring initial velocities
(5min at 27 C) in presence of saturating substrate concentration.
Reaction mixture comprises enzyme (24.5 ml of homogenate), in-
hibitor or DMSO (0.5 ml), ATP solution (10 ml) and DAG solution
(15 ml).
ATP solution contains and 0.25 mCi/ml (9.25 KBq/ml) of g32P
labelled radioactive ATP along with 25 mM normal unlabeled ATP,
50 mm MgCl2, 5 mm sodium orthovanadate and water to make up
the final volume.
DAG solution contains 1,2-dioleoyl-sn-glycerol (3 mg/ml) and
1mM EGTA in 25mM Hepes pH 8. DAG is stored in CH3OH:CHCl3
1:1 solution at 10 mg/ml, the required amount was dried using N2 or
vacuum centrifugation and sonicated extensively in ice could
buffer.
The reactionwas stopped after 5min by adding 200 ml of freshly
prepared 1M HCL and lipid extracted by adding 200 ml of
CH3OH:CHCl3 1:1 solution and vortexing for 1min. The two phases
were separated by centrifugation (12000 RCF for 2min). 25 ml of the
lower organic phase was spotted in small drops on silica TLC plates
(previously coated with (1.3% potassium oxalate and 5mM EDTA in
methanol and dried). Mobile phase was CHCl3:CH3OH:H2O:25%
NH4OH (60:47:11:4).
TLC was run 10 cm and dried before radioactive signals were
detected by GS-250 molecular imager and was quantified by
quantity one (Bio-Rad) software assuring the absence of saturated
spots.
Percentage residual activity was calculated as follows:
(OST-DGKa homogenate with inhibitor e vector homogenate)/
(OST-DGKa homogenate with DMSO e vector homogenate)
*100.4.8. Superoxide anion (O2) production
All the experiments were performed in triplicate using cells
isolated from each single donor.
Monocytes (250.000 cells/well) were treated for 1 h with the
indicated drugs (10 mM) with or without serotonin (1 mM). Then,
cells were stimulated with phorbol 12-myristate 13-acetate (PMA;
Sigma-Aldrich) 1 mM for 30min. PMA is awell-known stimulus that
induces a strong and significant respiratory burst via PKC activation
[35]. Superoxide anion production was then evaluated by the su-
peroxide dismutase (SOD)-sensitive cytochrome C (CytC) reduction
assay and expressed as nmoles cytochrome C reduced/106 cells/
30min, using an extinction coefficient of 21.1mM. To avoid inter-
ference with spectrophotometric recordings, cells were incubated
with RPMI 1640 without phenol red, antibiotics and FBS.
4.9. RICD assay in Jurkat cells
Treatments with inhibitors were done in 96-well flat-bottom
plate, pre-coated with anti CD3 (clone OKT3, 50 mg/ml) orphytohemagglutinin-P (PHA-P Sigma, 50 mg/ml) and incubated for
24 h at 4 C. To test restimulation induced cell death, the plate is
washed with medium and then cells were plated at concentration
of 0.5 105 cells/well in triplicate in RPMI-GlutaMAX medium in
presence or absence of 1 mM inhibitor or equivalent volume of
DMSO as a negative control. After 24 h incubation, live cells were
counted using trypan blue exclusion method and cell death is
expressed as % cell loss and calculated as:
% Cell Loss ¼ (100-(number of viable cells in sample/ number of
viable cells in control) x 100).
Results were expressed as mean± standard error mean (SEM) of
three or more replicate experiments.
4.10. RICD assay for SAP silenced T cells
Activated human PBLs were transfected with 200 pmol of siRNA
oligonucleotides specific for the target protein (Stealth Select
siRNA; Life Technologies) or a non-specific control oligo (Life
Technologies). Transient transfections were performed using
Amaxa nucleofector kits for human T cells (Lonza) and the Amaxa
Nucleofector II or 4D systems (programs T-20 or EI-115). Cells were
cultured in IL-2 (100 IU/ml) for 4 days to allow target gene
knockdown. Knockdown efficiency was periodically evaluated by
RT-PCR and Western blotting.
Non-specific Stealth RNAi Negative Control Duplexes
(12935e300, Life Technologies) were used as a negative control.
Sense strand UGUACUGCCUAUGUGUGCUGUAUCA Antisense
strand UGAUACAGCAGACAUAGGCAGUACA.
To test restimulation induced cell death, activated T cells
(105 cells/well) were plated in triplicate in 96-well round-bottom
plate and treated with anti-CD3 (clone OKT3) (1, 5, 10, 50, 100,
500 ng/ml) in RPMI-GlutaMAX supplemented with 100 IU/ml rhIL-
2 for 24 h. In these assays inhibitors (1, 5,10 mM)were added 30min
before the restimulationwith OKT3. 24 h after treatment, cells were
stained with 1 mg/ml propidium iodide and collected for a constant
time of 30 s per sample on a FACScan flow cytometer (FACScaliber
or Accuri C6, BD) or Attune Nxt Flow Cytometer (Thermo Fisher
Scientific). Cell death is expressed as % cell loss and calculated as:
% cell loss¼ 100-((number of viable cells in sample / number of
viable cells in control) x 100)
Results were expressed as mean± standard error mean (SEM).
4.11. Quantitative real-time PCR
Activated human PBLs were prepared and transfected as
described above. The RNA concentration and purity were estimated
by a spectrophotometric method using NanoDrop 2000c (Thermo
Scientific). The RNAwas retrotranscribed with High-Capacity cDNA
Reverse Transcription Kits (Applied Biosystems) and cDNA quan-
tified by real time PCR (ABI7900 Applied Biosystems) using GUSB as
normalizer.
TaqMan gene expression assays were from Life Technologies:
Hs00939627_m1 (glucuronidasi beta, GUSB), Hs00374226_m1
(NR4A1), Hs00545007_m1 (NR4A3).
4.12. Western blot analysis
To verify the expression of the DGKa in both MDCK cells
transfected with OST-Vector and OST-DGKa, and SAP in Jurkat cells
transfected with control-shRNA and SAP-shRNA, equal amounts of
protein lysates were prepared using 1% NP40 lysis buffer
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EGTA, 50mM NaF, 1% NP40, 10% glycerol, 1mM orthovanadate
alongwith protease inhibitors at PH 8.0. Proteinswere separated on
12% or 15% SDSePAGE gels and the resolved proteins were then
transferred to a polyvinylidene fluoride membrane. The mem-
branes were blocked by incubating with 3% (w/v) dried BSA for
1 h at room temperature. They were then incubated overnight with
respective primary antibodies at 4 C with gentle agitation: for
detecting DGKa we used anti-DGKa antibody from Abcam (Cam-
bridge, UK) and anti-SAP (SH2D1A-D10G8) from Cell signaling
(USA) diluted (1:500) in Tris-buffered saline with detergent Tween
20 (TBST) containing 3% (w/v) BSA. The membranes were then
washed 4 times in TBS tween buffer with 15min time interval. They
were then incubated with alkaline HRP-conjugated rabbit or mouse
secondary antibody (1:5000) from PerkinElmer (USA) diluted in
TBST, for 1 h at room temperature with gentle agitation. After four
15min washes with TBST, the membranes were developed using
the Western Chemiluminescence Substrate (PerkinElmer, USA).
4.13. Quantification and statistical analysis
Data for the screen on OST-DGKa homogenates are the mean of
duplicates. The compounds showing inhibitory activity in this assay
were tested >4 times and the mean± SEM is reported.
To calculate IC50 values of active inhibitors, the inhibitor activity
was measured at least three times at 0.1, 1.0, 10.0 and 100.0 mM
concentration. Data were analysed using [inhibitor] vs. normalized
response parameters with least square [ordinary] curve fitting
method in GraphPad PRISM 7.0 software mentioning 95% confi-
dence interval and IC50 values always greater than 0.0. Graph shows
the mean± SEM of inhibitor activity at the indicated concentration.
In all the experiments the data were normalized with the controls.
Evaluation of in vitro assays across multiple treatments (RICD)
were analysed by using one-way ANOVA (Figs. 6e8) and two-way
ANOVA (Fig. 9) with multiple comparisons correction using
GraphPad PRISM 7.0 software. Error bars are described in figure
legends as± SEM or± SD where appropriate. A single, double and
triple asterisk denotes significance of a p-value 0.05, 0.01
and 0.001 respectively in all experiments.
Funding
This work was supported by: Universita del Piemonte Orientale,
Fondazione Telethon (GGP16252, 2016), TIPSO grant from Regione
Piemonte (PAR FSC 2007e2013 Asse IdInnovazione e transizione
produttivadLinea di azione 3: “Competitivita industria e artigia-
nato” linea ddBando regionale sulle malattie Autoimmuni e
Allergiche), Consorzio Interuniversitario di Biotecnologie (CIB).
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ejmech.2018.12.061.
References
[1] Y.V. Shulga, M.K. Topham, R.M. Epand, Regulation and functions of diac-
ylglycerol kinases, Chem. Rev. 111 (2011) 6186e6208.
[2] I. Merida, A. Avila-Flores, E. Merino, Diacylglycerol kinases: at the hub of cell
signaling, Biochem. J. 409 (2008) 1e18.
[3] J. Cai, H. Abramovici, S.H. Gee, M.K. Topham, Diacylglycerol kinases as sources
of phosphatidic acid, Biochim. Biophys. Acta 1791 (2009) 942e948.
[4] F. Sakane, S. Imai, M. Kai, S. Yasuda, H. Kanoh, Diacylglycerol kinases as
emerging potential drug targets for a variety of diseases, Curr. Drug Targets 9
(2008) 626e640.
[5] F. Sakane, S. Imai, M. Kai, S. Yasuda, H. Kanoh, Diacylglycerol kinases: why so
many of them? Biochim. Biophys. Acta 1771 (2007) 793e806.[6] K.P. Bhat, K. Aldape, Not expecting the unexpected: diacylglycerol kinase
alpha as a cancer target, Cancer Discov. 3 (2013) 726e727.
[7] F. Sakane, S. Mizuno, S. Komenoi, Diacylglycerol kinases as emerging potential
drug targets for a variety of diseases: an update, Front. Cell Dev. Biol. 4 (2016)
82.
[8] S. Krishna, X.P. Zhong, Regulation of lipid signaling by diacylglycerol kinases
during T cell development and function, Front. Immunol. 4 (2013) 178.
[9] A.H. Filipovich, K. Zhang, A.L. Snow, R.A. Marsh, X-linked lymphoproliferative
syndromes: brothers or distant cousins? Blood 116 (2010) 3398e3408.
[10] D.T. Purtilo, D. DeFlorio, L.M. Hutt, J. Bhawan, J.P. Yang, R. Otto, W. Edwards,
Variable phenotypic expression of an X-linked recessive lymphoproliferative
syndrome, N. Engl. J. Med. 297 (1977) 1077e1080.
[11] B. Pasquier, L. Yin, M.C. Fondaneche, F. Relouzat, C. Bloch-Queyrat, N. Lambert,
A. Fischer, et al., Defective NKT cell development in mice and humans lacking
the adapter SAP, the X-linked lymphoproliferative syndrome gene product,
J. Exp. Med. 201 (2005) 695e701.
[12] L. Dupre, G. Andolfi, S.G. Tangye, R. Clementi, F. Locatelli, M. Arico, A. Aiuti, et
al., SAP controls the cytolytic activity of CD8þ T cells against EBV-infected
cells, Blood 105 (2005) 4383e4389.
[13] C.S. Ma, N.J. Hare, K.E. Nichols, L. Dupre, G. Andolfi, M.G. Roncarolo,
S. Adelstein, et al., Impaired humoral immunity in X-linked lymphoprolifer-
ative disease is associated with defective IL-10 production by CD4þ T cells,
J. Clin. Invest. 115 (2005) 1049e1059.
[14] A.L. Snow, R.A. Marsh, S.M. Krummey, P. Roehrs, L.R. Young, K. Zhang, J. van
Hoff, et al., Restimulation-induced apoptosis of T cells is impaired in patients
with X-linked lymphoproliferative disease caused by SAP deficiency, J. Clin.
Invest. 119 (2009) 2976e2989.
[15] G. Baldanzi, A. Pighini, V. Bettio, E. Rainero, S. Traini, F. Chianale,
P.E. Porporato, et al., SAP-mediated inhibition of diacylglycerol kinase a reg-
ulates TCR-induced diacylglycerol signaling, J. Immunol. 187 (2011)
5941e5951.
[16] E. Ruffo, V. Malacarne, S.E. Larsen, R. Das, L. Patrussi, C. Wülfing, C. Biskup, et
al., Inhibition of diacylglycerol kinase a restores restimulation-induced cell
death and reduces immunopathology in XLP-1, Sci. Transl. Med. 8 (2016),
321ra327.
[17] D.C. de Chaffoy de Courcelles, P. Roevens, H. Van Belle, R 59 022, a diac-
ylglycerol kinase inhibitor. Its effect on diacylglycerol and thrombin-induced
C kinase activation in the intact platelet, J. Biol. Chem. 260 (1985)
15762e15770.
[18] D. de Chaffoy de Courcelles, P. Roevens, H. Van Belle, L. Kennis, Y. Somers,
F. De Clerck, The role of endogenously formed diacylglycerol in the propa-
gation and termination of platelet activation. A biochemical and functional
analysis using the novel diacylglycerol kinase inhibitor, R 59 949, J. Biol.
Chem. 264 (1989) 3274e3285.
[19] M. Sato, K. Liu, S. Sasaki, N. Kunii, H. Sakai, H. Mizuno, H. Saga, et al., Evalu-
ations of the selectivities of the diacylglycerol kinase inhibitors r59022 and
r59949 among diacylglycerol kinase isozymes using a new non-radioactive
assay method, Pharmacology 92 (2013) 99e107.
[20] Y. Jiang, F. Sakane, H. Kanoh, J.P. Walsh, Selectivity of the diacylglycerol kinase
inhibitor 3-[2-(4-[bis-(4-fluorophenyl)methylene]-1-piperidinyl)ethyl]-2, 3-
dihydro-2-thioxo-4(1H)quinazolinone (R59949) among diacylglycerol kinase
subtypes, Biochem. Pharmacol. 59 (2000) 763e772.
[21] C.L. Dominguez, D.H. Floyd, A. Xiao, G.R. Mullins, B.A. Kefas, W. Xin,
M.N. Yacur, et al., Diacylglycerol kinase a is a critical signaling node and novel
therapeutic target in glioblastoma and other cancers, Cancer Discov. 3 (2013)
782e797.
[22] S. Boroda, M. Niccum, V. Raje, B.W. Purow, T.E. Harris, Dual activities of
ritanserin and R59022 as DGKa inhibitors and serotonin receptor antagonists,
Biochem. Pharmacol. 123 (2017) 29e39.
[23] R.L. McCloud, C.E. Franks, S.T. Campbell, B.W. Purow, T.E. Harris, K.L. Hsu,
Deconstructing lipid kinase inhibitors by chemical proteomics, Biochemistry
57 (2018) 231e236.
[24] C.E. Franks, S.T. Campbell, B.W. Purow, T.E. Harris, K.L. Hsu, The ligand binding
landscape of diacylglycerol kinases, Cell Chem. Biol. 24 (2017) 870e880, e875.
[25] S. Akhondzadeh, M. Malek-Hosseini, A. Ghoreishi, M. Raznahan,
S.A. Rezazadeh, Effect of ritanserin, a 5HT2A/2C antagonist, on negative
symptoms of schizophrenia: a double-blind randomized placebo-controlled
study, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32 (2008) 1879e1883.
[26] W.R. Bishop, B.R. Ganong, R.M. Bell, Attenuation of sn-1,2-diacylglycerol
second messengers by diacylglycerol kinase. Inhibition by diacylglycerol an-
alogs in vitro and in human platelets, J. Biol. Chem. 261 (1986) 6993e7000.
[27] P. Nasmith, S. Grinstein, Diacylglycerol kinase inhibitors R59022 and dio-
ctanoylethylene glycol potentiate the respiratory burst of neutrophils by
raising cytosolic Ca2þ, Biochem. Biophys. Res. Commun. 161 (1989) 95e100.
[28] C. Redman, J. Lefevre, M.L. MacDonald, Inhibition of diacylglycerol kinase by
the antitumor agent calphostin C. Evidence for similarity between the active
site of diacylglycerol kinase and the regulatory site of protein kinase C, Bio-
chem. Pharmacol. 50 (1995) 235e241.
[29] F. Colon-Gonzalez, M.G. Kazanietz, C1 domains exposed: from diacylglycerol
binding to protein-protein interactions, Biochim. Biophys. Acta 1761 (2006)
827e837.
[30] K. Liu, N. Kunii, M. Sakuma, A. Yamaki, S. Mizuno, M. Sato, H. Sakai, et al.,
A novel diacylglycerol kinase a-selective inhibitor, CU-3, induces cancer cell
apoptosis and enhances immune response, J. Lipid Res. 57 (2016) 368e379.
[31] P.C. Hawkins, A. Nicholls, Conformer generation with OMEGA: learning from
S. Velnati et al. / European Journal of Medicinal Chemistry 164 (2019) 378e390390the data set and the analysis of failures, J. Chem. Inf. Model. 52 (2012)
2919e2936.
[32] P.C. Hawkins, A.G. Skillman, A. Nicholls, Comparison of shape-matching and
docking as virtual screening tools, J. Med. Chem. 50 (2007) 74e82.
[33] S.W. Muchmore, A.J. Souers, I. Akritopoulou-Zanze, The use of three-
dimensional shape and electrostatic similarity searching in the identifica-
tion of a melanin-concentrating hormone receptor 1 antagonist, Chem. Biol.
Drug Des. 67 (2006) 174e176.
[34] G. Baldanzi, S. Cutrupi, F. Chianale, V. Gnocchi, E. Rainero, P. Porporato,
N. Filigheddu, et al., Diacylglycerol kinase-alpha phosphorylation by Src on
Y335 is required for activation, membrane recruitment and Hgf-induced cell
motility, Oncogene 27 (2008) 942e956.
[35] M. Talmon, S. Rossi, A. Pastore, C.I. Cattaneo, S. Brunelleschi, L.G. Fresu, Vor-
tioxetine exerts anti-inflammatory and immunomodulatory effects on human
monocytes/macrophages, Br. J. Pharmacol. 175 (2018) 113e124.
[36] J. Dhein, H. Walczak, C. B€aumler, K.M. Debatin, P.H. Krammer, Autocrine T-cell
suicide mediated by APO-1/(Fas/CD95), Nature 373 (1995) 438e441.
[37] F. Aoudjit, K. Vuori, Engagement of the alpha2beta1 integrin inhibits Fasligand expression and activation-induced cell death in T cells in a focal
adhesion kinase-dependent manner, Blood 95 (2000) 2044e2051.
[38] E. Rainero, C. Cianflone, P.E. Porporato, F. Chianale, V. Malacarne, V. Bettio,
E. Ruffo, et al., The diacylglycerol kinase a/atypical PKC/b1 integrin pathway in
SDF-1a mammary carcinoma invasiveness, PLoS One 9 (2014), e97144.
[39] S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, et al.,
PubChem substance and compound databases, Nucleic Acids Res. 44 (2016)
D1202eD1213.
[40] J.J. Irwin, T. Sterling, M.M. Mysinger, E.S. Bolstad, R.G. Coleman, ZINC: a free
tool to discover chemistry for biology, J. Chem. Inf. Model. 52 (2012)
1757e1768.
[41] Shoichet Irwin, ZINC–a free database of commercially available compounds
for virtual screening, J. Chem. Inf. Model. (2005) 177e182.
[42] P.C. Hawkins, A.G. Skillman, G.L. Warren, B.A. Ellingson, M.T. Stahl, Conformer
generation with OMEGA: algorithm and validation using high quality struc-
tures from the Protein Databank and Cambridge Structural Database, J. Chem.
Inf. Model. 50 (2010) 572e584.
